Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Impact of Brentuximab Vedotin in Patients with Breast Implant-Associated Anaplastic Large Cell Lymphoma with Capsule Infiltration Requiring Chemotherapy

Blood (2023) 142 (Supplement 1): 4439.

https://doi.org/10.1182/blood-2023-188896

Published: 2023

Journal Articles

Axicabtagene Ciloleucel As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Primary Analysis of Alycante, a Phase 2 Lysa Study

Roch Houot, Emmanuel Bachy, Guillaume Cartron, François-Xavier Gros, Franck Morschhauser, Lucie Oberic, Thomas Gastinne, Pierre Feugier, Remy Dulery, Catherine Thieblemont, Magalie Joris, Francisco Llamas-Gutierrez, Emmanuel Itti, Cedric Menard, Yassine Al-Tabaa, Clement Bailly, Marie-Helene Delfau, Camille Laurent, Francois Lemonnier

Blood (2022) 140 (Supplement 1): 410–411.

https://doi.org/10.1182/blood-2022-156626

Published: 2022

Journal Articles

A Molecular Classifier Increased the Accuracy of Lymphoma Diagnosis By Expert Pathologists in the Diffuse Large B-Cell Lymphoma Gained Trial from the Lysa

Blood (2021) 138 (Supplement 1): 3495.

https://doi.org/10.1182/blood-2021-152144

Published: 2021

Journal Articles

Breast Implant Associated-Anaplastic Large-Cell Lymphoma (BIA-ALCL): Data Based on the Lymphoma Study Association (LYSA) Registry. Promising Results of Brentuximab Vedotin Combined with Cyclophosphamide, Doxorubicin and Prednisone (BV-CHP) As First Line Treatment for Patient Requiring Chemotherapy

Blood (2021) 138 (Supplement 1): 1387.

https://doi.org/10.1182/blood-2021-150478

Published: 2021

Journal Articles

Integrative Study of a High-Grade B-Cell Lymphoma Cohort of 45 Patients: A Single Institution Real Life Study

Louise Roulin, Elsa Poullot, Paul Blanc-Durand, Cyrielle Robe, Francois Lemonnier, Fabien Le Bras, Romain Gounot, Karim Belhadj, Jehan Dupuis, Mohammad Hammoud, Taoufik El Gnaoui, Sebastien Mule, Christiane Copie Bergman, Thierry Molina, Marie Helene Delfau Larue, Emmanuel Itti, Philippe Gaulard, Corinne Haioun

Blood (2021) 138 (Supplement 1): 4576.

https://doi.org/10.1182/blood-2021-152627

Published: 2021

Journal Articles

Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA

Blood (2021) 137 (17): 2307–2320.

https://doi.org/10.1182/blood.2020008750

Published: 2021

Includes: Supplemental data

Journal Articles

Nivolumab in Combination with Gemcitabine and Oxaliplatin (GemOx) in Relapse/Refractory T-Cell Lymphoma: Preliminary Results of the Experimental Arm of the Niveau Trial

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-136941

Published: 2020

Journal Articles

Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL): The Lymphoma Study Association (LYSA) Registry Data

Blood (2019) 134 (Supplement_1): 4021.

https://doi.org/10.1182/blood-2019-129123

Published: 2019

Journal Articles

Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Refractory/Relapsed (R/R) DLBCL. a Real Life Study in Patients Ineligible for Autologous Transplantation

Clarisse Cazelles, Karim Belhadj, Helene Vellemans, Vincent Camus, Christiane Copie, MD PhD, Liana Veresezan, MD, Emmanuel Itti, MD PhD, Stephanie Becker, MD, Muriel verlinde Carvalho, Jehan Dupuis, MD, Fabien Le Bras, Francois Lemonnier, MD PhD, Louise Roulin, MD, Taoufik El Gnaoui, Fabrice Jardin, Nicolas Mounier, MD, Herve Tilly, MD PhD, Corinne Haioun, MD PhD

Blood (2019) 134 (Supplement_1): 4115.

https://doi.org/10.1182/blood-2019-124143

Published: 2019

Journal Articles

Clinical, Immunophenotypic and Genetic Characteristics of Aggressive (non-Burkitt) B-Cell Lymphoma in a Real Life Cohort

Blood (2019) 134 (Supplement_1): 4122.

https://doi.org/10.1182/blood-2019-123259

Published: 2019

Journal Articles

Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL): The French Lymphoma Study Association (LYSA) Registry Data

Blood (2018) 132 (Supplement 1): 1641.

https://doi.org/10.1182/blood-2018-99-111659

Published: 2018

Journal Articles

Obinutuzumab Versus Rituximab in Combination with ACVBP-14 or CHOP-14 Following a PET-Driven Strategy in Aa-IPI 1-3 DLBCL Patients (< 60 years): Third Planned Interim and Final Analyses of the Gained Trial

Blood (2017) 130 (Supplement 1): 190.

https://doi.org/10.1182/blood.V130.Suppl_1.190.190

Published: 2017

Journal Articles

Low Suvmax Measured on Baseline FDG-PET/CT and Elevated β2 Microglobulin Are Negative Predictors of Outcome in High Tumor Burden Follicular Lymphoma Treated By Immunochemotherapy: A Pooled Analysis of Three Prospective Studies

Anne Ségolène Cottereau, MD, Annibale Versari, MD, Loïc Chartier, Jehan Dupuis, MD, Vittoria Tarantino, MD, Rene-Olivier Casasnovas, MD, Antonella Franceschetto, Emmanuel Itti, MD PhD, Hervé Tilly, MD PhD, Corinne Haioun, MD, Massimo Federico, MD PhD, Alina Berriolo, MD, Gilles Andre Salles, MD PhD, Stefano Luminari, Michel Meignan, MD PhD, Judith Trotman, MBChB

Blood (2016) 128 (22): 1101.

https://doi.org/10.1182/blood.V128.22.1101.1101

Published: 2016

Journal Articles

Prognostic Value of Baseline Quantitative PET Metrics for Patients with Unfavourable Early Stage Hodgkin Lymphoma Enrolled in the Standard Arm of the EORTC/Lysa/FIL H10 Trial

Blood (2016) 128 (22): 184.

https://doi.org/10.1182/blood.V128.22.184.184

Published: 2016

Journal Articles

Number of Circulating t(14;18) Tumor Cells at Diagnosis Is Related to, but Add to the Prognostic Value of Metabolic Tumor Burden in Follicular Lymphoma

Marie-Helene Delfau-Larue, MD PhD, Isabelle Nel, PD, Axel VAN Der Gucht, MD, Gaelle Laboure, MD, Benjamin Verret, MD, Salma Hamdane, PD, Philippe Gaulard, MD PhD, Michel Meignan, MD PhD, Corinne Haioun, MD PhD, Christiane Copie-Bergman, MD PhD, Jehan Dupuis, MD, Emmanuel Itti, MD PhD

Blood (2015) 126 (23): 3872.

https://doi.org/10.1182/blood.V126.23.3872.3872

Published: 2015

Journal Articles

Baseline Metabolic Tumor Volume Is Predictive of Patient Outcome in Diffuse Large B Cell Lymphoma

Rene-Olivier Casasnovas, MD, Myriam Sasanelli, MD, Alina Berriolo-Riedinger, MD, Franck Morschhauser, MD, PhD, Emmanuel Itti, MD, PhD, Damien Huglo, MD, PhD, Annibale Versari, MD, Bertrand Coiffier, MD, PhD, Michel Meignan, MD, PhD

Blood (2012) 120 (21): 1598.

https://doi.org/10.1182/blood.V120.21.1598.1598

Published: 2012

Journal Articles

Early 18 fluorodeoxyglucose PET Scan as a Prognostic Tool in Diffuse Large B-Cell Lymphoma Patients Treated with An Anthracycline-Based Chemotherapy Plus Rituximab.

Violaine Safar, Jehan Dupuis, Fabrice Jardin, Christophe Fruchart, Stéphane Bardet, Pierre Vera, Herve Tilly, Michel Meignan, Emmanuel Itti, Corinne Haioun

Blood (2009) 114 (22): 98.

https://doi.org/10.1182/blood.V114.22.98.98

Published: 2009

Journal Articles

Prognostic Value of Early 18fluorodeoxyglucose PET Scan in Patients with Diffuse Large B Cell Lymphoma Treated with Rituximab Plus CHOP or High-Dose CHOP.

Jehan Dupuis, Emmanuel Itti, Christophe Fruchart, Stéphane Bardet, Alain Rahmouni, Jean-Pierre Vilque, Chieh Lin, Karim Belhadj, Taoufik El Gnaoui, Frédérique Kuhnowski, Michel Meignan, Corinne Haioun

Blood (2008) 112 (11): 2006.

https://doi.org/10.1182/blood.V112.11.2006.2006

Published: 2008

Journal Articles

Response Assessment after an Inductive CHOP or CHOP-Like Regimen with or without Rituximab in 103 Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Integrating 18 Fluorodeoxyglucose Positron Emission Tomography (PET) to the International Workshop Criteria (IWC).

Jehan Dupuis, MD, Emmanuel Itti, MD,PhD, Alain Rahmouni, MD,PhD, Jean-Didier Rain, MD,PhD, Christian Gisselbrecht, MD,PhD, Karim Belhadj, MD, Taoufik El Gnaoui, MD, Isabelle Gaillard, MD, Chieh Lin, MD, Nicolas Mounier, MD,PhD, Philippe Gaulard, MD,PhD, Michel Meignan, MD,PhD, Felix Reyes, MD,PhD, Corinne Haioun, MD

Blood (2006) 108 (11): 2735.

https://doi.org/10.1182/blood.V108.11.2735.2735

Published: 2006

Journal Articles

Early Response Evaluation with 18 FDG-PET Scanning, but Not Phenotypic Profile, Are Predictive of Outcome in Diffuse Large B-Cell Lymphoma.

Jehan Dupuis, Philippe Gaulard, Emmanuel Itti, Alain Rahmouni, François Hemery, Josette Brière, Bettina Fabiani, Christiane Copie-Bergman, Christian Gisselbrecht, Michel Meignan, Félix Reyes, Corinne Haioun

Blood (2005) 106 (11): 1914.

https://doi.org/10.1182/blood.V106.11.1914.1914

Published: 2005

NARROW

Impact of Brentuximab Vedotin in Patients with Breast Implant-Associated Anaplastic Large Cell Lymphoma with Capsule Infiltration Requiring Chemotherapy

Axicabtagene Ciloleucel As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Primary Analysis of Alycante, a Phase 2 Lysa Study

A Molecular Classifier Increased the Accuracy of Lymphoma Diagnosis By Expert Pathologists in the Diffuse Large B-Cell Lymphoma Gained Trial from the Lysa

Breast Implant Associated-Anaplastic Large-Cell Lymphoma (BIA-ALCL): Data Based on the Lymphoma Study Association (LYSA) Registry. Promising Results of Brentuximab Vedotin Combined with Cyclophosphamide, Doxorubicin and Prednisone (BV-CHP) As First Line Treatment for Patient Requiring Chemotherapy

Integrative Study of a High-Grade B-Cell Lymphoma Cohort of 45 Patients: A Single Institution Real Life Study

Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA

Nivolumab in Combination with Gemcitabine and Oxaliplatin (GemOx) in Relapse/Refractory T-Cell Lymphoma: Preliminary Results of the Experimental Arm of the Niveau Trial

Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL): The Lymphoma Study Association (LYSA) Registry Data

Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Refractory/Relapsed (R/R) DLBCL. a Real Life Study in Patients Ineligible for Autologous Transplantation

Clinical, Immunophenotypic and Genetic Characteristics of Aggressive (non-Burkitt) B-Cell Lymphoma in a Real Life Cohort

Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL): The French Lymphoma Study Association (LYSA) Registry Data

Obinutuzumab Versus Rituximab in Combination with ACVBP-14 or CHOP-14 Following a PET-Driven Strategy in Aa-IPI 1-3 DLBCL Patients (< 60 years): Third Planned Interim and Final Analyses of the Gained Trial

Low Suvmax Measured on Baseline FDG-PET/CT and Elevated β2 Microglobulin Are Negative Predictors of Outcome in High Tumor Burden Follicular Lymphoma Treated By Immunochemotherapy: A Pooled Analysis of Three Prospective Studies

Prognostic Value of Baseline Quantitative PET Metrics for Patients with Unfavourable Early Stage Hodgkin Lymphoma Enrolled in the Standard Arm of the EORTC/Lysa/FIL H10 Trial

Number of Circulating t(14;18) Tumor Cells at Diagnosis Is Related to, but Add to the Prognostic Value of Metabolic Tumor Burden in Follicular Lymphoma

Baseline Metabolic Tumor Volume Is Predictive of Patient Outcome in Diffuse Large B Cell Lymphoma

Early 18 fluorodeoxyglucose PET Scan as a Prognostic Tool in Diffuse Large B-Cell Lymphoma Patients Treated with An Anthracycline-Based Chemotherapy Plus Rituximab.

Prognostic Value of Early 18fluorodeoxyglucose PET Scan in Patients with Diffuse Large B Cell Lymphoma Treated with Rituximab Plus CHOP or High-Dose CHOP.

Response Assessment after an Inductive CHOP or CHOP-Like Regimen with or without Rituximab in 103 Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Integrating 18 Fluorodeoxyglucose Positron Emission Tomography (PET) to the International Workshop Criteria (IWC).

Early Response Evaluation with 18 FDG-PET Scanning, but Not Phenotypic Profile, Are Predictive of Outcome in Diffuse Large B-Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only